Geneos Therapeutics Secures $17 Million In Series A2 Financing To Advance Personalized Cancer Immunotherapy Platform
Geneos Therapeutics Secures $17 Million In Series A2 Financing To Advance Personalized Cancer Immunotherapy Platform
03/24/22, 3:00 AM
Money raised
$17 million
Round Type
series a
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies, announced today that it has secured $17 million in Series A2 financing. The financing was led by Flerie Invest with participation from all existing Series A investors including Santé Ventures, Korea Investment Partners (KIP) – Global Bio Fund, and INOVIO Pharmaceuticals, Inc. (NASDAQ: INO). In conjunction with the financing, Dr
Company Info
Additional Info
At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment. Our passion is to develop personalized therapies to unleash the most powerful force against cancer – patients' own immune system. Our approach using our GT-EPICTM platform is to target unique neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel and personalized treatments for cancer. We have an experienced management team with a track record of success in building immunotherapy-based companies.